The cell-surface protein APO-1 is a member of the nerve growth factor (NGF)/tumor necrosis factor (TNF) receptor superfamily. APO-1 mediates apoptosis in susceptible cells upon stimulation with the monoclonal antibody anti-APO-1 or upon binding of its natural ligand. Soluble receptors had previously been identified for most members of the NGF/TNF receptor superfamily. Recently, a soluble form of APO-1 (SAPO-1) was described. We established a sandwich enzyme-linked immunosorbent assay to detect SAPO-l in culture supernatants of human cell lines and in human sera.
fluids.23-28 Thus, the biologic effects of TNF were inhibited by soluble(s) TNF receptors in v i t r~.~"~~ Although the physiologic functions of these soluble receptors are not completely clarified, it is conceivable that they play a role in regulating functions of the immune system. For many leukemic diseases and some solid tumors, eg, colon carcinoma, elevated levels of sTNF receptors or CD30 have been found and, in some cases, correlated with disease p r o g r e~s i o n . '~~*~~~~-~' Elevated SAPO-l levels have been reported in sera from SLE patients. Therefore, it is conceivable that changes in SAPO-I level are associated with abnormal growth regulation of lymphoid cells.'3
Accessibility of mAP0-l is essential for ligand binding and triggering of apoptosis. Soluble forms of other members of the TNF/NGF receptor family were shown to prevent binding of the ligand to the cell surface receptor. Injection of SAPO-l into mice altered lymphocyte development signifi~ant1y.I~ Thus, SAPO-l may prevent cells from undergoing APO-1 ligand-induced apopt~sis.'~.'~ Hence, secretion of SAPO-l may provide a mechanism for tumor cells to escape immunosurveillance and may be involved in leukemogenesis.
Therefore, we investigated whether SAPO-l could be detected in sera from patients with different leukemic diseases. A sandwich enzyme-linked immunosorbent assay (sELISA) was established and used to detect SAPO-l in culture supernatants and in sera from patients with different leukemic diseases.
lymphomas of the centrocytic and centroblastic subtype (according to the Kiel clas~ification'~) or of the small cleaved and large noncleaved subtype, respectively (according to the New Working Formulation of the World Health Organizati~n~~.'~); common acute lymphoblastic leukemia (CALL); and T-ALL were obtained at the time of diagnosis before antileukemic therapy from the Childrens Hospital and the Medizinische Klinik V, University of Heidelberg (Heidelberg, Germany).
Baculovirus expression andpurijcation of mAP0-I. The cDNA encoding the complete human APO-1 molecule was recombined into Autographa califomica baculovirus (AcNPV) using the transfer vector pVL 1393 (Dianova, Hamburg, Germany). Recombinant viruses were isolated as previously described?6 Sf9 cells were infected with recombinant virus with a multiplicity of infection of 10 and harvested after 3 days. mAP0-1 was extracted as d e~c r i b e d~~.~' with 2.5% Tween-40 and solubilized with 2% sodium desoxycholate. The protein solution obtained was further purified by affinity chromatography on an anti-APO-l (IgG3)-coupled Sepharose 4B column (Pharmacia, Freiburg, Germany). Purified fractions were loaded on a reversed-phase high performance liquid chromatography (HPLC) column (PLRP-S, 300 A, 8 pm, 250 X 4.6 mm; Polymer Laboratories, Shropshire, UK) and eluted in an acetonitrile gradient from 5% to 70% in 0.1% (voVvol) trifluoric acid (TFA). Sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE 10%) showed two protein bands of 48 and 52 k D , reflecting different glycosylated forms of the recombinant mAP0-I. Dimerization and multimerization of the purified mAP0-1 molecule were also observed.
Production and purification of rabbit anti-APO-I Igs. Adult male New Zealand white rabbits were immunized subcutaneously with 50 pg recombinant purified mAP0-I, mixed 1:l (voYvol) with complete Freunds adjuvant (GIBCO) in a final volume of 200 pL. Booster injections were performed with 50 pg purified mAP0-l mixed 1:l (vol/voi) with incomplete Freunds adjuvant every 4 weeks. Affinity purification of Igs from rabbit serum was performed on a protein A sepharose 4B column (Pharmacia). The serum was adjusted to pH 8 and loaded onto the column. After washing with 100 mmoVL Tris, pH 8, and 10 mmoVL Tris, pH 8, Ig was eluted with 100 mmoVL glycine-HC1 (pH 3). Fractions collected were analyzed for purity on reducing 10% SDS-PAGE gels and pure fractions were pooled for use in the sELISA.
To ensure that the sELISA detected the extracellular part of APO-1, we tested the rabbit anti-APO-l serum in a functional assay. Hut-78 cells were incubated with the antiserum and apoptosis was detected with the JAM-Assay3* ([3H] thymidine release) and by observation of membrane blebbing, formation of apoptotic bodies, and chromatin condensation. No apoptosis inducing activity was observed with the preimmune serum (data not shown).
sELISA for detection of SAPO-I in human serum. ELISA plates (Falcon, Heidelberg, Germany) were coated with 100 &/well of the murine MoAb anti-APO-l (IgG3, 1 ~g / m L )~ in NaHC03, pH 9.6, at 4°C for 12 hours. Coated plates were washed three times with 100 pL phosphate-buffered saline (PBS) containing 0.05% Tween-20 (PBSRween) and subsequently blocked with 2% bovine serum albumin (BSA) in PBSEween for 30 minutes at room temperature. Undiluted culture Supernatants or human sera were added in log 4 dilutions and incubated for 1.5 hours. The serum samples were centrifuged before addition at 17,300g for 10 minutes. The plates were washed as above and purified rabbit anti-APO-l Ig, diluted in culture medium, was added and incubated for 1.5 hours. After three washes, peroxidase-conjugated mouse antirabbit Ig, absorbed against mouse, human, sheep, and goat serum proteins (Dianova, Hamburg, Germany), in PBSlTween was added for 1.5 hours. Staining was developed after another wash cycle with 75 pL substrate solution (0.1% orthophenylenediamine in 0.05 m o K citric acid, 0.1 m o m Na2HP04) for 10 minutes and the reaction was stopped by the addition of 25 pL 3N H,S04. The results were read with an ELISA reader (EAR 400AT LAB. Instruments, Grodig, Austria) at 492 nm. For standardization, all assays were controlled with standard sera from healthy donors and with purified recombinant mAP0-1. The amount of recombinant mAP0-l was determined in a silverstained 10% SDS-PAGE by comparison with BSA. The detection limit for recombinant mAP0-l in the sELISA was 2 ng/mL. Interassay variation was less than 6% and intraassay variation less than 22%. Within assay variations, the reproducibility of the sELISA was 100%.
The validity of the sELISA was confirmed by the following tests. (1) Sera and culture Supernatants from SKW6.4 cells were supplemented with increasing amounts of recombinant mAPO-l similar to those present in positive patient sera and assayed as above. In all cases, mAP0-1 was quantitatively recovered. (2) Only background levels were seen in the sELISA after preabsorption of positive controls with 100 pg/mL of the coating antibody. (3) Precipitation of SAPO-l in SAPO-l-containing sera with anti-APO-l -coupled sepharose beads resulted in an 85% decrease of the signal in the sELISA. The same procedure performed with an isotype-matched control antibody did not affect the sELISA results. (4) Assay readings were not affected by clotting time (range, 1 to 24 hours), the use of plasma (collected with heparin) instead of serum, or by freezing and thawing the sera. Thus, the possibility that SAPO-l released by leukocytes in response to clotting contributed to any extent to the measured serum levels of SAPO-l was ruled out. (5) Multiple testing of the same samples always resulted, within assay variations, in the same ELISA readings.
Immunoprecipitation and Westem blotting. Serum samples were preabsorbed for 12 hours at 4°C by incubation with l5 pg control antibody coupled to protein A sepharose beads. SAPO-l was subsequently precipitated for 12 hours at 4°C with 15 pg anti-APO-l (IgG3) coupled to protein A sepharose beads. After washing in a solution containing 0.1% NP-40, 1 mmol/L vanadate, 1 mmol/L PMSF, 30 mmol/L Tris, pH 7.5, 10 mmol/L NaF, and 150 mmol/L NaCl, beads were resuspended in 60 pL 5X SDS-PAGE sample buffer and denatured for 2 minutes at 95°C. Samples were run on a 12% SDS-PAGE gel under nonreducing conditions. Proteins were transfered onto nitrocellulose membranes by electroblotting (1 .S hours at 0.8 &cm2). Subsequently, the membranes were saturated with 5% nonfat dry milk powder in PBS.
After 30 minutes, the blocking solution was removed and biotinylated monoclonal anti-APO-I (IgG3, 1 pg/mL) diluted in PBSmween was added for 1.5 hours. Membranes were washed with PBSlTween and subsequently incubated for 1 hour with biotinylated streptavidin-horseradish peroxidase (HRPO) conjugate (Amersham, Frankfurt, Germany) diluted in PBSEween, followed by another washing step. Protein bands were developed using the enhanced chemiluminescence (ECL) method (Amersham, Frankfurt, Germany) and light emission was detected on Kodak XAR-5 X-ray films (Kodak, Stuttgart, Germany).
Statistics. Data sets of the groups studied were not symmetrically distributed. Thus, observed serum concentrations did not show a normal distribution. Because underlying distributions were the same for all groups, the Wilcoxon rank sum test was used for individual comparison of control and experimental groups. Exact P values were computed for all comparisons. For an explicit protection of false rejecting the null hypothesis, the computed P values were compared with a Bonferoni-corrected value of the significance level a = .05.39 supernatants and human sera, we established a sensitive sEL-ISA. Using purified recombinant mAP0-1, the sensitivity of the sELISA was found to be 2 ng/mL (OD,,, = 0.3 = 30 U/mL; dashed line in Fig 1A) . Detection was not affected by using recombinant mAP0-1 in either culture medium or human serum. Even undiluted human serum could be used, indicating that human serum proteins did not interfere with the sELISA. All sELISAs were performed with recombinant mAPO-I as a standard. Interassay variation was less than 6% and intra-assay variation was less than 22% ( Fig 1A) . sELISA values reflected the APO-1 content of the samples because immunoprecipitation with an anti-APO-1 antibody resulted in a strong reduction of the sELISA signal by depletion of APO-1 from the sample (Fig 1B) . Specificity of the sELISA was further confirmed by the addition of recombinant mAPO-1 to SAPO-1 -containing serum or culture supernatants. In all tested samples complete recovery of added purified recombinant mAP0-1 was seen (data not shown). Thus, our sELISA detected APO-1 in a quantitative way in cell culture supernatants and in human sera. Increased serum levels of SAPO-I in B-and T-cell leukemias. The first set of experiments was designed to identify SAPO-l in culture supernatants of various mAPO-1 expressing B-and T-cell leukemia cell lines6 Unconcentrated supernatants did not show the presence of SAPO-l. However, in 100-fold concentrated supernatants, SAPO-l was clearly detected. The concentrated supernatants of the T-cell lines Hut-78 and Jurkat contained 280 and 300 U/mL of SAPO-1, respectively. Similar concentrations were detected in the concentrated supernatant of the B-lymphoblastoid cell line SKW6.4 (320 U/mL).
RESULTS

Validity
The finding of SAPO-l in SKW6.4 cell culture supernatants prompted us to analyze the presence of SAPO-l in serum from patients with various leukemic diseases. The SAPO-l was determined by sELISA in sera from patients (n = 143) with B-and T-cell leukemias. These leukemias included progenitor cell-derived T-ALL, CALL, and leukemias of a more advanced maturation stage such as HCL, CLL, and centroblastic and centrocytic B-cell lymphomas (Fig 2) . Sera from T-ALL and CALL were obtained from pediatric patients; all other sera were from adult patients. The corresponding control sera were obtained from age-matched children for the pediatric group and from healthy adults, respectively. The sera analyzed were taken at time of diagnosis before antileukemic therapy. Control sera contained negligible quantities of SAPO-l, whereas leukemic sera showed SAPO-I levels up to 210 U/mL. Patients with CALL, T-ALL, HCL, CLL, and centrocytic and centroblastic B-cell lymphomas showed increased levels of SAPO-1 in the serum. Using recombinant mAP0-1 as a standard, we found approximately 2 ng/mL (30 U/mL) SAPO-l in the sera of healthy donors. The difference of levels of SAPO-l in our control sera compared with the control sera in the report by Cheng et all3 might be attributed to technical differences in the ELISA.
To assess the relation between standard disease parameters and SAPO-l levels, we compared factors indicating tumor cell burden such as white blood cell count or risk factors as defined by Berlin-Frankfurt-Munster (BFM) leukemia protocols (blast count or extent of hepatosplenomegaly) with SAPO-l levels in all patients. No correlation was found indicating that SAPO-l levels are not determined by tumor load but rather by the biology of the tumor.
Comparison of SAPO-l levels with karyotype and bcl-2
For expression did not show any correlations, eg, T-ALL have low bcl-2 expression, whereas c-ALL showed high bcl-2 expression. Both of these leukemias had elevated levels of SAPO-l. Therefore, SAPO-l levels seem not to be directly related with standard disease parameters of the leukemias analyzed.
In addition to leukemic disorders of the immune system, we also analyzed a cohort of human immunodeficiency virus (HIV)-infected children for SAPO-l (n = 367). These sera contained no detectable levels of SAPO-l, despite the fact that SAPO-l expression on T cells in HIV-1 -infected children is greatly increased. This finding shows that the presence of high numbers of mAP0-l -positive cells is not always correlated with elevated SAPO-l level^.^.^'
To determine whether SAPO-1 in culture supernatants and in human sera represents the complete APO-1 molecule, a proteolytic cleavage, or a splice product, its molecular weight was analyzed. SAPO-l was purified from the supematant of SKW6.4 B-lymphoblastoid cells by immunoprecipitation with anti-APO-1 -coupled protein A beads. The precipitates were analyzed by SDS-PAGE and Western blotting with biotinylated monoclonal anti-APO-1 (IgG3). As shown in Fig 3A, purified SAPO-l from culture supernatant had similar properties as the purified recombinant baculovirusexpressed mAPO-1. In both cases, APO-1 migrated as a protein band of 48 to 52 k D . Reduction of recombinant mAP0-1 and deglycosylation resulted in a single band at 39 k D , as described' (data not shown). Therefore, the higher molecular weight bands observed at 96 and 150 kD represent SDS-stable dimers and trimers of mAP0-l. Aggregates were even observed at low concentrations of recombinant mAP0-1 (Fig 3A, lanes 3 through 5) . This finding shows the strong tendency of mAPO-1 to form dimers and multimers. Unconcentrated culture supernatant was also analyzed and, consis- Furthermore, sELISA-positive sera from leukemic patients and sELISA-negative control sera were tested for the presence of SAPO-l by immunoprecipitation and Western blotting. Figure 3B shows that SAPO-l in two sELISA-positive sera appeared as a band of 96 kD on the Western blot (Fig 3B, lanes 1 and 2) . Occasional preparations also showed a minor band at 48 to 52 kD (data not shown). No SAPO-l was detectable in a control serum (Fig 3B, lane 3) . SAPO-l in sera, therefore, showed a tendency to dimerize like SAPO-1 in SKW6.4 cell culture supernatants (Fig 3A) , mAPO-l purified from SKW6.4 membranes,' and recombinant baculovirus-expressed mAP0-1. In two cases in which CLL patients have been completely resistant to therapy, we observed constantly elevated SAPO-l levels. In contrast, other patients with normal response to therapy showed variable SAPO-l levels. Sera obtained from patients 1 to 3 years after successful antileukemic therapy showed normal levels of SAPO-l (data not shown).
The specificity of our test system to detect SAPO-l in human sera was further evident from experiments in which purified recombinant mAP0-1 was added to control sera and quantitatively recovered by sELISA (data not shown). In addition, binding of dimerized or multimerized SAPO-l from human sera in the sELISA (Fig 4, 0) was competed by soluble anti-APO-l antibody (100 pg/mL IgG3), and only -30 a background sELISA signal was detected (Fig 4, W) . Specificity was again shown by the fact that the addition of isotype-matched control antibody did not change the sELISA results significantly (Fig 4. U) .
DISCUSSION
We have identified SAPO-l in culture supernatants of Tand B-cell leukemias using an sELISA. In addition, we compared SAPO-l levels in normal human sera with SAPO-l levels in sera from patients with CALL, T-ALL, HCL, CLL, and B-cell lymphomas. Increased SAPO-1 levels were found in sera from all leukemias examined. SAPO-l from the culture supernatant of SKW6.4 cells and from sera of leukemic patients was further analyzed. The molecular weight of SAPO-1 was found to be similar to that of the purified recombinant baculovirus-expressed mAPO-1 and to that of mAPO-I purified from the lymphoblastoid B-cell line SKW6.4.' A common feature of all APO-I preparations was the tendency to form dimers and multimers. This phenomenon is also known for other soluble receptors, eg, sCD58."
Evidence is accumulating that many cell surface receptors also occur as soluble receptors. Soluble receptors for the following cytokines have been identified: interleukin-lo (IL-IL-2,"' IL-4,"5 IL-6,"" IL-7:' and interferon-y.4x In   Fig 3. (A) Western blot analysis of SAPO-l in concentrated SKW6.4 cell culture supernatant. Comparison to the purified recombinant mAPO-1, expressed in the baculovirus system. After concentration, the culture supernatant was precleared with control antibodycoupled protein A beads and subsequently precipitated with anti-APO-l-coupled protein A beads. Precipitated proteins were separated by SDS-PAGE under nonreducing conditions, transferred t o nitrocellulose, and detected with biotinylated anti-APO-1 and biotinylated streptavidin-HRPO conjugate using the ECL method. Lane 1, 1,000~ concentrated SKW6.4 cell culture supernatant. Lane 2, unconcentrated SKW6.4 cell culture supernatant. Lanes 3 through 5, purified recombinant mAPO-1 in serial twofold dilutions from left to the right. (B) Western blot analysis of SAPO-l in serum samplesfrom leukemic patients. Samples were processed as described in Fig 1 but omitting the concentration step. Blot lal was developed with biotinylated anti-APO-l (1 pg1 mL, lgG3) and biotinylated streptavidin-HRPO using the ECL method. Lanes 1 and 2, serum samples from leukemic patients containing approximately 200 U/ mL SAPO-l. Lane 3, sELISA-negative control serum from a healthy donor. Blot Ibl was developed with biotinylated control antibody llgG3) and biotinylated streptavidin-HRPO using the ECL method. Lanes 4 through 6, aliquots of the same sera as mentioned for blot (a) were loaded onto the gel. Blot (a) showed t w o sera with a predominant dimeric form of SAPO-1. In other serum preparations, a minor additional band of monomeric SAPO-l at 48 t o 52 kD was observed (not shown).
addition, soluble receptors have been described for members of the TNFNGF receptor family. Three different types of soluble NGF receptors identified by molecular weight have been described. Recent experiments suggested various mechanisms for the generation of soluble receptors. One mechanism, as shown for the NGF receptor and the TNF receptor type 11, is cleavage from the cell surface by proteoly~is.~~.~' Likewise, a 32-kD sCD27 molecule was shown to be cleaved from its 55-kD membrane-bound counterpart. Loenen et all* showed that the sCD27 and the mCD27 were derived from the same mRNA. Furthermore, both soluble and membrane forms of the TNF receptor type I were described. They were probably derived from the same transcript and are indistinguishable by molecular weight and A soluble form of APO-I was recently described that is generated by differential splicing, yielding a secreted molecule lacking the transmembrane region.I3 This deletion of 19 amino acids would not be resolved on SDS-PAGE (Fig 3) . We found a similar molecular weight of SAPO-l and mAPO-I in Westem blot analysis. Culture of SKW6.4 in the presence of protease inhibitors did not result in a change of the amount of SAPO-I detected (data not shown). Therefore, our data are consistent with the finding that SAPO-l is a splice variant of mAPO-I rather than a product of proteolytic cleavage. The amount of SAPO-l detected in culture supernatants of various cell lines was about 3 U/rnL. However, in sera of leukemic patients, levels of up to 210 U/mL SAPO-l were observed. The variations seen in serum samples from individual patients within the same leukemia group correspond to variations seen with other soluble receptors such as sTNF receptors in HCL.'4 All cell lines examined showed strong mAPO-I expression. In contrast, mAPO-I expression of leukemic cells from patients with B-lineage leukemias/ lymphomas (CALL, CLL, and HCL) was low or Only cells from patients with T-ALL were strongly APO-I po~itive.'~ Thus, SAPO-l in serum of leukemic patients may not always be derived from the leukemic cells and serum levels may not always be correlated with mAPO-I expression on the leukemic cells. Another putative source of SAPO-1 may be T and B cells, reflecting the activation status of these cells. However, because SAPO-l was constantly high in patients relatively resistant to antileukemic therapy, SAPO-l detection in sera could serve as a putative marker for an active persisting leukemia. This hypothesis is supported by the finding that, after successful therapy, SAPO-l levels returned to normal values. In addition, SAPO-l levels are not elevated in sera from a cohort of HIV-infected children (n = 367), in which mAPO-I expression is greatly increased on the patients' T cell^.^^,^' Because lymphocyte depletion by apoptosis is observed in acquired immunodeficiency syndrome (AIDS) and may involve the APO-I system, this observation also supports the concept that SAPO-1 may prevent APO-I -mediated lymphocyte death.
Tumor cells may have a greater tendency than nonmalignant cells to produce and shed soluble forms of cell surface proteins.ss Thus, leukemic cells might switch from production of mAPO-I to production of SAPO-l to escape APO-I ligand-induced apoptosis. Escape from ligand-induced CD54 also gives rise to a soluble form shown to inhibit lysis of melanoma cells by natural killer cells."3 It is tempting to speculate that production of SAPO-l in combination with shedding of other molecules, such as CD54, might provide tumor cells with a mechanism to escape immunosurveillance and apoptosis. Future work will be directed at identifying the cells producing SAPO-l found in the sera of leukemic patients. In addition, conditions for production of SAPO-l will have to be characterized and might provide the means to selectively manipulate malignant diseases. Thus, a shift in production from SAPO-l to mAPO-I might render cells sensitive to APO-I -mediated apoptosis and to therapeutic intervention.
way.'-' I.57-hl Furthermore, injection into mice of agonistic
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